ASEP Medical develops a diagnostic assay for the early and rapid identification of sepsis, enabling timely risk assessment and targeted treatment. The company also offers a patented pharmaceutical peptide that effectively targets biofilm infections, addressing a critical gap in current treatment options for antibiotic-resistant infections.
Funding
$988.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sepsis diagnosis relies on slow, culture-based methods, delaying treatment and increasing mortality. Biofilm infections, which are highly resistant to antibiotics, lack effective treatment options, leading to persistent infections and complications.
Solution
ASEP Medical is developing a rapid diagnostic assay for early sepsis identification, enabling timely intervention and improved patient outcomes. The company also offers a patented pharmaceutical peptide designed to target and disrupt biofilm infections, addressing the limitations of current antibiotic therapies. This peptide can also be used as a substrate-independent coating to maintain sterile medical devices and implants.
Target Audience
The primary target audience includes hospitals, clinical laboratories, and healthcare providers seeking improved diagnostic and therapeutic solutions for sepsis and biofilm-related infections.
Features
- Rapid sepsis diagnostic assay for early risk assessment and targeted treatment
- Patented pharmaceutical peptide that targets biofilm infections
- Peptide coatings for sterile medical devices and implants